-transparent.png){kind=logo}
Eleven patients over 70 years of age and two patients under 60 years of age with myeloblastic leukemia have been treated with low doses of cytarabine (10 mg per m2 every 12 hours by subcutaneous injection for a median duration of 3 weeks). Four patients of the first group went into complete remission, 2 patients in the older age group and the 2 patients under 60 years of age went into partial remission, while only 3 patients out of 13 (23%) did not respond to this treatment. Sometimes severe cytopenia observed during the induction phase counterbalanced the advantages of treatment (simplicity and absence of systemic toxicity) and suggest an antimitotic effect which is probably associated with differentiation of the malignant clone.
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
January 2001,
Voprosy onkologii,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
August 1984,
Ugeskrift for laeger,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
June 1985,
Seminars in oncology,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
August 1985,
Cancer,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
February 1990,
Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
January 1987,
Haematologica,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
January 1987,
Anticancer research,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
October 1984,
British journal of haematology,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
October 1994,
Ugeskrift for laeger,
P Beris, and
A Rieder, and
C Andrey, and
C Helg, and
B Chapuis
January 1985,
Haematology and blood transfusion,
